BI 2536

Catalog No.S1109

BI 2536 Chemical Structure

Molecular Weight(MW): 521.66

BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.

Size Price Stock Quantity  
In DMSO USD 240 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock
USD 997 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 55 Publications

13 Customer Reviews

  • (C) HeLa cells were treated with inhibitors of Aurora B (hesperadin), Aurora A (Aurora A inhibitor I), CDK1 (roscovitine), or PLK1 (BI2536) for 2 hours before immunostaining for tubulin and phosphorylated RV[S/T]F (p-RV[S/T]F). Nuclei are indicated with DAPI. Control cells were not treated with any inhibitor. More than 50 cells were imaged for each condition in three independent experiments. Scale bar, 20 μm.

    Science, 2018, 11(530), doi: 10.1126/scisignal.aai8669. BI 2536 purchased from Selleck.

    Comparison between Genetic Ablation of Cdc20 and Current Mitotic Drugs (C) Transformed Cdc20(lox/lox); RERT(+/Cre) MEFs were subcutaneously injected into the two flanks of SCID mice, and tumors were scored every 2-3 days.These mice were injected i.p. (three injections per week) with 4-OHT or mitotic drugs (taxol, vincristine, and BI2536) when tumors reached about 200 mm3 of volume (day 11; arrow) (n = 8 mice per group). (D) Representative images of these fibrosarcomas 3 days after injection with 4-OHT (to generate Cdc20(D/D) cells), BI2536, or taxol. These mice were injected with 10 μM BrdU to score DNA replication. CA3, immunodetection of active caspase 3. Scale bars, 50 or 10 μM (insets).

    Cancer Cell 2010 18, 641–654. BI 2536 purchased from Selleck.

  • (a,b) RPE1 cells transfected with control or either of two B56-PP2A siRNA pools (1, 2) were incubated in MG132 (10µM, 15 min), followed by the addition of BI2536 (40 nM) or DMSO for 45 min. (a) The frequency of mitotic cells with few or absent cold-stable K-bres . (b) Maximum-intensity projection of tubulin (green) and an overlay with kinetochores (CREST, red) in B56-PP2A-siRNA (pool 2) cells treated with DMSO or BI2536 (40 nM). Insets are 3 enlargement of the optical sections spanning the outlined centromeres.

    Nat Cell Biol 2011 13, 1265-71. BI 2536 purchased from Selleck.

    (a) HeLa Tet-On cells were treated with the indicated siRNAs, arrested in mitosis using 500 nM nocodazole (Noc) and 10 μM MG132, and then treated with or without BI 2536. The endogenous Cdc20 was immunoprecipitated from these cells and blotted with the indicated antibodies. The mitotic index of each sample is indicated below each lane. The bottom graph shows the quantification of the Cdc20-pS92 signal normalized to the total Cdc20 signal (mean±range; n=2 independent experiments).

    Nat Commun, 2016, 7:10818. BI 2536 purchased from Selleck.

  • Treatment with BI 2536 induces cell-cycle arrest in NB TICs and aberrant accumulation of cyclin B1 and p21. C, expression of cyclin B1 and p21 was assessed in NB88R2 following 16 and 24-hour treatment with different doses of BI 2536 (10, 30, and 100 nmol/L). ERK1 (extracellular signal regulated kinase 1) was used as the loading control. D, inhibition of PLK1 was assessed by in vitro kinase assay following treatment of NB88R2 for 3 hours with BI 2536.

    Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck.

    Treatment with BI 2536 induces cell death via apoptosis. A,treatment with BI 2536 (10, 30, and 100 nmol/L) reduces viable cell numbers as assessed by trypan blue exclusion. B, representative Western blot demonstrating accumulation of cleaved PARP following treatment with 10 nmol/L BI 2536.

    Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck.

  • BI 2536 inhibits NB tumor growth in vivo. A and B, NOD/SCID mice bearing 50- to100-mm3 tumors were injected intravenously with either vehicle (0.1N HCl per saline) or 12.5 to 25 mg/kg BI 2536 for 2 consecutive days a week, for a total of 3 cycles.Two independent experiments were performed in each case with 5 animals per group. Representative tumor growth data are shown.

     

     

    Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck.

    animals with 50- to 100-mm3 tumors were randomized into 4 groups: group 1 injected intravenously with vehicle (0.1N HCl per saline), group 2 injected intravenously with 12.5 mg/kg of BI 2536 (2 consecutive days, 3 cycles), group 3 injected i.p. with 10 mg/kg of irinotecan (3 doses total, 3 days apart), and group 4 injected with BI 2536 and irinotecan. Both representative tumor growth data and a Kaplan-Meyer survival plot are shown.

    Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck.

  • Plk-1 knockdown and inhibition by BI 2536 and viability of human melanoma cell lines M14 and WM-115 as demonstrated by MTT assay. Experiments were performed in triplicate. One representative experiment is shown. *P<0.001, ANOVA test with Tukey’s post-test. ANOVA, analysis of variance; MTT, 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Plk-1, polo-like kinase 1; siRNA, small-interfering RNA; WB, western blot.

    J Invest Dermatol 2011 131, 1886–1895. BI 2536 purchased from Selleck.

    Western blot analysis of the expression and phosphorylation of Plk1, and phosphorylation of Myt1 in the CSC-like cells after treatment with BI 2536 for 24 and 48 hours, respectively.

    Oncotarget, 2017, 8(23):37633-37645. BI 2536 purchased from Selleck.

  • Cells with decreased GRK5 expression are more sensitive to PLK1 inhibition.A , shown is cell death in control or GRK5-shRNA stably transfected cells after 72 h of treatment with 0-120 nM BI 2536 as determined by trypan blue exclusion (n = 6).B , shown is cell death in control or GRK5-shRNA stably transfected cells after 72 h treatment with 0 –120 nM GSK461364, as determined by trypan blue exclusion ( n = 4).

    J Biol Chem 2012 287(21), 17088-99. BI 2536 purchased from Selleck.

    J Biomol Screen 2013 18(1), 54-66. BI 2536 purchased from Selleck.

  • Example dose response curves of the PLK-1 inhibitor BI-2536. During the large dose response study for each reference compounds 8 dilutions were tested. Curves for IC50 determination for two independent experiments for the PLK1 inhibitor BI-2536 are displayed. This inhibitor is also used to achieve the LC values. IC50 has been determined with 7.48 +/- 0.09 log [M] and 6.75 +/- 0.21 log [M]. Correlating assay performance data are displayed in Suppl. Fig. 5. 

    J Biomol Screen 2013 18(1), 54-66. BI 2536 purchased from Selleck.

Purity & Quality Control

Choose Selective PLK Inhibitors

Biological Activity

Description BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.
Features The first potent and selective Plk1 inhibitor that induces all hallmarks of Plk1 inhibition.
Targets
PLK1 [1]
(Cell-free assay)		 PLK2 [1]
(Cell-free assay)		 PLK3 [1]
(Cell-free assay)
0.83 nM 3.5 nM 9.0 nM
In vitro

BI 2536 blocks the activities of Plk2 and Plk3 to a slightly lesser extent with IC50 of 3.5 nM and 9.0 nM, respectively. In HeLa cells, BI 2536 treatment ranging from 10-100 nM leads to the blocking of the recruitment of γ-tubulin and phosphorylation of Apc6 at mitotic centrosomes, inhibition of cohesin release from chromosome arms, induction of monopolar spindles, as well as a range of other mitotic processes that are known to depend on Plk1. BI 2536 treatment leads to the HeLa cells arrested in G2/M, subsequently a sub-G1 DNA peak indicative of DNA breakdown and apoptosis, and accumulated cleaved PARP p85 fragments in a concentration-dependent manner. BI 2536 inhibits the growth of a panel of 32 human cancer cell lines with EC50 of 2-25 nM, while blocking the proliferation of exponentially growing hTERT-RPE1, human umbilical vein endothelial cells (HUVECs), and normal rat kidney (NRK) cells with EC50 of 12-31 nM. [1] Plk1 inhibition by BI 2536 reduces the growth and viability of anaplastic thyroid carcinoma (ATC) cells such as CAL62, OCUT-1, SW1736, 8505C, and ACT-1 with EC50 values of 1.4-5.6 nM. [2]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PSN1 NFT4PXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWGyNGNtUUN3ME2wMlAxPzd4IN88US=> M2PjRXNCVkeHUh?=
ACN MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\kRWlEPTB;MD6wNFg1OyEQvF2= MV;TRW5ITVJ?
TE-8 NX\UWlRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwMEC5OFEh|ryP NVT4[ok1W0GQR1XS
LC-2-ad MmOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TDSWlEPTB;MD6wNVA6OyEQvF2= MYXTRW5ITVJ?
ALL-PO M17MeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml76TWM2OD1yLkCxN{DPxE1? NEHsR|RUSU6JRWK=
EW-16 M2fHUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXXPXNKSzVyPUCuNFE{OzZizszN M3jsUXNCVkeHUh?=
KM12 NYPYeIttT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrVNWJKSzVyPUCuNFE{PDhizszN NGW3[INUSU6JRWK=
GI-1 NUjIb3JVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfDWGFKSzVyPUCuNFE{QDNizszN MnXhV2FPT0WU
LS-411N M4ezc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTWTWM2OD1yLkCxOFA4KM7:TR?= MmftV2FPT0WU
ES8 NGO4N|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrETWM2OD1yLkCxOFk1KM7:TR?= MnjqV2FPT0WU
SNU-C2B MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTBwMEG1NlYh|ryP NGPhT|dUSU6JRWK=
CESS M{HZemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwMEG2NFIh|ryP MYHTRW5ITVJ?
697 MnPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTBwMEG2Olgh|ryP MVrTRW5ITVJ?
NCI-H1963 MmPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTBwMEG2O|Mh|ryP M{jXc3NCVkeHUh?=
IA-LM NWjnW2J[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLhVHV7UUN3ME2wMlAyPjh6IN88US=> Mkf1V2FPT0WU
SW954 NVnlbnVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jXWGlEPTB;MD6wNVcxPSEQvF2= MmLYV2FPT0WU
RL95-2 MnrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwMEG3N|gh|ryP Mor4V2FPT0WU
LXF-289 M4XTSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHsTWM2OD1yLkCxO|ch|ryP NIrQOpdUSU6JRWK=
OCUB-M NWPuXpVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TaTGlEPTB;MD6wNVgzPiEQvF2= MmDJV2FPT0WU
RKO MlPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnNTWM2OD1yLkCxPVg4KM7:TR?= NXXkPW9{W0GQR1XS
LOUCY NEnqSWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXWNGdKSzVyPUCuNFIxPSEQvF2= NFfRfIZUSU6JRWK=
NOS-1 NWHGOGpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnMOnVlUUN3ME2wMlAzODl|IN88US=> NGK1V4dUSU6JRWK=
A4-Fuk MkT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwMEKyNVgh|ryP M3Oxe3NCVkeHUh?=
A388 NVzzRZhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvOR5VHUUN3ME2wMlAzOjJ5IN88US=> NWHoT2VzW0GQR1XS
TE-9 NHvSO4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnUeo1uUUN3ME2wMlAzOjZzIN88US=> NHfCeWVUSU6JRWK=
KURAMOCHI MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX35[Wp1UUN3ME2wMlAzOjh3IN88US=> MVTTRW5ITVJ?
KALS-1 MnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;hOWlEPTB;MD6wNlM{QCEQvF2= MV7TRW5ITVJ?
HOP-62 MkXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjpTJd{UUN3ME2wMlAzPDJizszN NWmzOpM5W0GQR1XS
RPMI-8402 NWmxfVFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Hu[GlEPTB;MD6wNlUxQCEQvF2= MYXTRW5ITVJ?
TE-1 M1H1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVK2UXdJUUN3ME2wMlAzPTF{IN88US=> MYrTRW5ITVJ?
CCRF-CEM NYjBOYQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1voR2lEPTB;MD6wNlU1OyEQvF2= MWjTRW5ITVJ?
HUTU-80 MlTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljQTWM2OD1yLkCyOlI1KM7:TR?= NWTXVGVWW0GQR1XS
NCI-H1648 NWL2fmxwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jwTmlEPTB;MD6wNlY1PyEQvF2= MUnTRW5ITVJ?
HCE-4 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TzSmlEPTB;MD6wNlY5OiEQvF2= M{HVWXNCVkeHUh?=
ETK-1 MmizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGS1OXJKSzVyPUCuNFI4OzZizszN MUPTRW5ITVJ?
TE-15 NEfCfZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTBwMEK3N|gh|ryP NEXWV|ZUSU6JRWK=
BE-13 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwMEK3OEDPxE1? Mk\UV2FPT0WU
KE-37 M2HpdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoH6TWM2OD1yLkCyO|QyKM7:TR?= NWnMbmcxW0GQR1XS
NCI-H1355 NH3STFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUG1elg3UUN3ME2wMlAzPzh|IN88US=> NWPvWGxVW0GQR1XS
TE-11 MnnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFeydG1KSzVyPUCuNFI5ODlizszN MlztV2FPT0WU
BL-70 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\BVGlEPTB;MD6wNlg2PyEQvF2= MVjTRW5ITVJ?
ES6 NVzWZ41zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHkNmQ2UUN3ME2wMlAzQDhzIN88US=> NWO4TXFQW0GQR1XS
GT3TKB NVOyZZk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zTW2lEPTB;MD6wNlk2OyEQvF2= NIrBRVRUSU6JRWK=
LB647-SCLC M1Hic2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUC0ZpBzUUN3ME2wMlA{OTl3IN88US=> NYnTWJNNW0GQR1XS
NB13 M{fKU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwMEOzNVYh|ryP M3T2c3NCVkeHUh?=
ST486 M2qyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTUbFA5UUN3ME2wMlA{OzN5IN88US=> MX3TRW5ITVJ?
NCI-H82 MmH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGD4R3pKSzVyPUCuNFM{PDNizszN NXK3[2IyW0GQR1XS
NTERA-S-cl-D1 NGXXU4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrzTWM2OD1yLkCzN|k6KM7:TR?= MnHFV2FPT0WU
ES4 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzXTWM2OD1yLkCzOFY{KM7:TR?= NYf3OYY4W0GQR1XS
SK-NEP-1 M3LicWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HWRWlEPTB;MD6wN|Q6QSEQvF2= NWfkbXRDW0GQR1XS
Becker NW\vUmU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTBwMEO1OVUh|ryP MlPOV2FPT0WU
A101D NULv[FBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnWwTWM2OD1yLkCzO|Q5KM7:TR?= Mn3ZV2FPT0WU
SK-UT-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\jbI9GUUN3ME2wMlA{Pzd2IN88US=> NYKySHFLW0GQR1XS
SW982 M3fUfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVyzRYNpUUN3ME2wMlA{PzlizszN M2nQVXNCVkeHUh?=
TE-10 NFPR[|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLpTWM2OD1yLkC0NFQ3KM7:TR?= MUjTRW5ITVJ?
OVCAR-4 M3rib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTBwMESwOVkh|ryP M4X2[3NCVkeHUh?=
KP-N-YS MkP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm[2TWM2OD1yLkC0NFg2KM7:TR?= MV3TRW5ITVJ?
BL-41 M4X6d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfEO|ZmUUN3ME2wMlA1OTJ3IN88US=> M2XJ[3NCVkeHUh?=
MZ1-PC M2rFbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTjTWM2OD1yLkC0NVI4KM7:TR?= MVvTRW5ITVJ?
PF-382 NGS0bXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDRTWM2OD1yLkC0NVk5KM7:TR?= Mom0V2FPT0WU
MOLT-13 MkThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPmT2hKSzVyPUCuNFQzOzhizszN MWnTRW5ITVJ?
HCC1599 MnuyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPaTWM2OD1yLkC0NlU5KM7:TR?= NVvPO5VHW0GQR1XS
IST-MEL1 NH6yXWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\UUGlEPTB;MD6wOFQ1OiEQvF2= NEHHeFZUSU6JRWK=
LU-139 NFjocoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTBwMES0OFIh|ryP NWDucG9uW0GQR1XS
MS-1 NYHzbYpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPXdY1iUUN3ME2wMlA1PzBzIN88US=> M{HiNHNCVkeHUh?=
MFH-ino NF72RYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XRfmlEPTB;MD6wOVAxOyEQvF2= NHS2fohUSU6JRWK=
IMR-5 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\lTWM2OD1yLkC1NFIyKM7:TR?= MkfCV2FPT0WU
TE-5 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\aOmlEPTB;MD6wOVA3OyEQvF2= M3nadnNCVkeHUh?=
DJM-1 NE[0NpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTBwMEWxOFIh|ryP MVLTRW5ITVJ?
NB17 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTBwMEWyNFch|ryP M1TXTnNCVkeHUh?=
KARPAS-45 M4XxU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwMEWzOVgh|ryP NInvXphUSU6JRWK=
TGBC1TKB MmPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwMEW0NFUh|ryP M1jQ[XNCVkeHUh?=
ML-2 NXniPZhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwMEW0NVQh|ryP NGC4UIRUSU6JRWK=
no-10 NXW3SXE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nUcWlEPTB;MD6wOVQ4PCEQvF2= NXfjXpBlW0GQR1XS
CTV-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;TTVRKSzVyPUCuNFU2ODJizszN NIDDUpBUSU6JRWK=
SJSA-1 MmrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\RZmlKSzVyPUCuNFU2OiEQvF2= MUTTRW5ITVJ?
HC-1 NX3IVGt7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nme2lEPTB;MD6wOVU6PyEQvF2= NVP4cIZOW0GQR1XS
TE-12 NF65XGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mof3TWM2OD1yLkC1OlE{KM7:TR?= MkD4V2FPT0WU
KY821 NX;wWpdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\ZZWlEPTB;MD6wOVY{OiEQvF2= NUe3[XN2W0GQR1XS
TALL-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFr1U2RKSzVyPUCuNFU4ODhizszN M3PONHNCVkeHUh?=
DEL NYDUSHQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwMEW3NFkh|ryP NVux[pZCW0GQR1XS
TE-6 M4HS[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTBwMEW3NlIh|ryP NELTVYFUSU6JRWK=
SK-LMS-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfSTWM2OD1yLkC1PFA2KM7:TR?= NHPRRWJUSU6JRWK=
EW-1 NYj1NFI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkO1TWM2OD1yLkC1PFM4KM7:TR?= M3TUTHNCVkeHUh?=
8-MG-BA Mmj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLkeZVlUUN3ME2wMlA2QDVzIN88US=> MnfSV2FPT0WU
NALM-6 MnO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwMEW5O|Mh|ryP M{f6[nNCVkeHUh?=
LB771-HNC M3jEWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGf4SYZKSzVyPUCuNFU6PzlizszN MWPTRW5ITVJ?
HT-144 NVHFdWdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHOW4l2UUN3ME2wMlA3OTNizszN MYHTRW5ITVJ?
KM-H2 NXywZ2ZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{flZ2lEPTB;MD6wOlIzOSEQvF2= MmrLV2FPT0WU
SF268 Ml7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDnUZhKSzVyPUCuNFYzQDZizszN MmPZV2FPT0WU
RS4-11 NF61VlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fqWmlEPTB;MD6wOlMxPCEQvF2= NXPCRXdyW0GQR1XS
MHH-PREB-1 M2n5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEW3PHpKSzVyPUCuNFY{OTlizszN NX70PGplW0GQR1XS
ATN-1 NXW4cXdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnz[XNKSzVyPUCuNFY{PDVizszN MoLWV2FPT0WU
BB30-HNC M2T1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPCdZVNUUN3ME2wMlA3PDN4IN88US=> MlfmV2FPT0WU
CPC-N NX3PcFBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLjTWM2OD1yLkC2OVI1KM7:TR?= MonVV2FPT0WU
NB1 NV;PV2d5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTBwME[2NVMh|ryP M2XRbHNCVkeHUh?=
KS-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU[2dJJuUUN3ME2wMlA3PzR6IN88US=> NGHIPWxUSU6JRWK=
RXF393 NF7Sc2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPTd3dKSzVyPUCuNFY4PjRizszN MX\TRW5ITVJ?
IST-SL2 M{Picmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljhTWM2OD1yLkC3NFA1KM7:TR?= MVTTRW5ITVJ?
GI-ME-N MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlr6TWM2OD1yLkC3Nlg3KM7:TR?= M3PVUHNCVkeHUh?=
VA-ES-BJ NGXxSHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHSTWM2OD1yLkC3OFc2KM7:TR?= MVHTRW5ITVJ?
NCI-H1581 NInsUmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TFUmlEPTB;MD6wO|Q4QCEQvF2= MUDTRW5ITVJ?
U-266 NUDCOpJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVKwWZp5UUN3ME2wMlA4PDl5IN88US=> M37rOHNCVkeHUh?=
DMS-114 M{jUWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorUTWM2OD1yLkC3OVI5KM7:TR?= NVW5TGVlW0GQR1XS
NCI-H187 NIXIPWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInNXlJKSzVyPUCuNFc4OjZizszN NYXkSJRpW0GQR1XS
SW962 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{K2NWlEPTB;MD6wO|g{QSEQvF2= MoDCV2FPT0WU
MONO-MAC-6 M3yxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\tfGJKSzVyPUCuNFc6QDZizszN NE\2[lZUSU6JRWK=
MOLT-16 NIfybGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4K5bmlEPTB;MD6wPFEzOSEQvF2= M3z0V3NCVkeHUh?=
KNS-42 NV\PeJN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zmWGlEPTB;MD6wPFE3OSEQvF2= NGHVNVRUSU6JRWK=
CMK NI\RR21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTBwMEiyNlUh|ryP MWLTRW5ITVJ?
Ramos-2G6-4C10 NGTvbotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETEVFZKSzVyPUCuNFgzOjVizszN NFPsc2JUSU6JRWK=
Daudi M3jBSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwMEiyOVYh|ryP MkXQV2FPT0WU
NCI-H510A NGrzNHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwMEizN|Yh|ryP M4jqb3NCVkeHUh?=
LB831-BLC M4PvOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfJSpVKSzVyPUCuNFg2PjFizszN MULTRW5ITVJ?
HEL MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUThOGV7UUN3ME2wMlA5PjZ6IN88US=> NFX2XVhUSU6JRWK=
LU-134-A NGjldYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnUeJNKSzVyPUCuNFg4ODhizszN NWXUboR3W0GQR1XS
NCI-H1694 MlnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjNfZNKSzVyPUCuNFg4PDRizszN M3XDbnNCVkeHUh?=
KGN NFnlVGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\TOGlEPTB;MD6wPFc2QSEQvF2= M{fTNnNCVkeHUh?=
A253 NUPrdpFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\OPWlEPTB;MD6wPFgzOiEQvF2= MXjTRW5ITVJ?
DG-75 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFn0VmZKSzVyPUCuNFg6OjJizszN MkfiV2FPT0WU
MOLT-4 Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwMEi5PFMh|ryP NXnB[lZMW0GQR1XS
NCI-SNU-5 NUnvdnZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fFNGlEPTB;MD6wPVI2QCEQvF2= MXjTRW5ITVJ?
ONS-76 NWTwVWFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\sTWM2OD1yLkC5Nlc3KM7:TR?= MknSV2FPT0WU
NCI-H446 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3v2Z2lEPTB;MD6wPVQ3OiEQvF2= MmfoV2FPT0WU
COR-L279 MnTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vKdWlEPTB;MD6wPVU2PiEQvF2= NGrmXYNUSU6JRWK=
Calu-6 Mkn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXv3OZM1UUN3ME2wMlA6PTl6IN88US=> MYPTRW5ITVJ?
BC-3 NWDCUmloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;CTWM2OD1yLkC5OlYzKM7:TR?= M3jofHNCVkeHUh?=
NCI-H2126 NEHQZlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHUR4hKSzVyPUCuNFk4QTFizszN MXzTRW5ITVJ?
NCI-H1882 NWjDeG1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHz3TohKSzVyPUCuNFk5ODlizszN NWPBVIdNW0GQR1XS
BB65-RCC NH;NXohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwMUCyPVQh|ryP NHy0SGNUSU6JRWK=
DU-4475 MoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33vUGlEPTB;MD6xNFQxPyEQvF2= M4jFVnNCVkeHUh?=
NCI-H526 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\rfGlEPTB;MD6xNFQ1KM7:TR?= NFLHVoVUSU6JRWK=
NEC8 NGSy[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofRTWM2OD1yLkGwOVI2KM7:TR?= M4LQO3NCVkeHUh?=
NCI-H1304 MoTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13YWWlEPTB;MD6xNFU6PCEQvF2= NFHNb45USU6JRWK=
L-540 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXm4dGtiUUN3ME2wMlExPzB6IN88US=> NVrpXoMxW0GQR1XS
NCI-SNU-16 NUPWcGE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHlN2oyUUN3ME2wMlExPzR{IN88US=> NH3ZOIFUSU6JRWK=
HD-MY-Z NH7uc5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTBwMUC4OVYh|ryP NITCcnlUSU6JRWK=
K-562 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXldpFyUUN3ME2wMlExQDV6IN88US=> MVXTRW5ITVJ?
JAR NUH0dYRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfUV2NKSzVyPUCuNVA6OjVizszN NXj5b2RjW0GQR1XS
MZ2-MEL NHX4OJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jz[mlEPTB;MD6xNVA2KM7:TR?= Mlv3V2FPT0WU
L-363 M{\xU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWC3UXJ[UUN3ME2wMlEyODd7IN88US=> NGm4S4VUSU6JRWK=
BV-173 NHzjPIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwMUGyOFMh|ryP NUHC[ZpMW0GQR1XS
NCI-H524 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwMUGyO|Qh|ryP NXfqVIZkW0GQR1XS
EoL-1-cell M3XTSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\4eWlEPTB;MD6xNVY4OiEQvF2= NGDWXo1USU6JRWK=
K052 NULMeZdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\FTWM2OD1yLkGxO|EzKM7:TR?= NW\iPHlwW0GQR1XS
TK10 M2HoeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\BR2lEPTB;MD6xNVczQCEQvF2= MV;TRW5ITVJ?
KU812 NX;2SJI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\vTWM2OD1yLkGyNFQ1KM7:TR?= NVnqU3JHW0GQR1XS
RPMI-8226 NFnkcHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwMUKwOVIh|ryP NXrVN4NrW0GQR1XS
MZ7-mel NFPHdYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwMUKyN|ch|ryP NWrSZXNxW0GQR1XS
SK-PN-DW NEnPdHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXGydYpGUUN3ME2wMlEzOjh5IN88US=> MlTlV2FPT0WU
SR M1G5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3xXlE4UUN3ME2wMlEzPDRzIN88US=> M{XVNnNCVkeHUh?=
RPMI-6666 NXXLUHZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13yPWlEPTB;MD6xNlc1OyEQvF2= NW\ITnA2W0GQR1XS
no-11 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrnbJBKSzVyPUCuNVI5PjlizszN MUHTRW5ITVJ?
EW-3 NHL3TIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTBwMUK4PVMh|ryP MXfTRW5ITVJ?
LAMA-84 NGf1fZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwMUOxPFch|ryP M3HYc3NCVkeHUh?=
HT NWnUfpRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHUSWJKSzVyPUCuNVM2PzRizszN NFrYOoVUSU6JRWK=
KP-N-RT-BM-1 NV7wNG9RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHHVIJmUUN3ME2wMlE{PjF{IN88US=> MUjTRW5ITVJ?
NCI-H747 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTMfll{UUN3ME2wMlE{PyEQvF2= M1PVV3NCVkeHUh?=
NCCIT MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYixRZk6UUN3ME2wMlE{QTN7IN88US=> MYPTRW5ITVJ?
MLMA MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml33TWM2OD1yLkG0NVY4KM7:TR?= MnjTV2FPT0WU
LP-1 MmrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwMUSyOEDPxE1? MXjTRW5ITVJ?
CAL-148 M1X2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTiTWM2OD1yLkG0OFg{KM7:TR?= M3vkOHNCVkeHUh?=
GB-1 M12wSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTBwMUS1NlYh|ryP MlvJV2FPT0WU
COR-L88 NIHBPYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVT3fY05UUN3ME2wMlE1QDB{IN88US=> NUD2Zo5FW0GQR1XS
NKM-1 NIDP[29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXpTWM2OD1yLkG0PVA3KM7:TR?= Mk[wV2FPT0WU
NB5 MmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnGbW9KSzVyPUCuNVU1PjJizszN MoXqV2FPT0WU
SH-4 M3H0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnlTWM2OD1yLkG1OFY3KM7:TR?= M4jXNXNCVkeHUh?=
EM-2 MkTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlm1TWM2OD1yLkG1OFY4KM7:TR?= Mo\BV2FPT0WU
TGBC24TKB NX;vfolmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfxTWM2OD1yLkG1OlU6KM7:TR?= MUPTRW5ITVJ?
SCLC-21H NEnSUo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXoUFBKSzVyPUCuNVU4ODJizszN NXTyVnhRW0GQR1XS
COLO-684 Mm\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTBwMUW3NlEh|ryP MkLNV2FPT0WU
KINGS-1 NVfHTVhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHTTWM2OD1yLkG1PVEh|ryP NFrjVnpUSU6JRWK=
LS-123 NGDteJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\uSWlEPTB;MD6xOVkyPyEQvF2= MmGxV2FPT0WU
MC116 NXPGR2NRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwMU[xOVgh|ryP MXzTRW5ITVJ?
SU-DHL-1 MmXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3L5T2lEPTB;MD6xOlIxPiEQvF2= MoTVV2FPT0WU
NCI-H64 M3LYfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljxTWM2OD1yLkG2N|Q4KM7:TR?= NUHifYNTW0GQR1XS
HCE-T MoLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHpXW1KSzVyPUCuNVY2ODRizszN M2HRS3NCVkeHUh?=
LOXIMVI M1jEc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrI[pVZUUN3ME2wMlE3QTR7IN88US=> MWLTRW5ITVJ?
ARH-77 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XFeGlEPTB;MD6xO|M4QSEQvF2= M3XacHNCVkeHUh?=
DOHH-2 M2rWZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlqyTWM2OD1yLkG3OlczKM7:TR?= MUDTRW5ITVJ?
COLO-320-HSR M3K5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGW5NlhKSzVyPUCuNVgyPTRizszN NV\PfmJ5W0GQR1XS
NB6 M{TtcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljsTWM2OD1yLkG4OVY3KM7:TR?= MYjTRW5ITVJ?
L-428 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonmTWM2OD1yLkG4PFE{KM7:TR?= NGT4SWdUSU6JRWK=
SNB75 NIriOGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwMUi4NlQh|ryP NIP2S45USU6JRWK=
NCI-H2141 NVWzb2dKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nTfWlEPTB;MD6xPVAyOSEQvF2= MY\TRW5ITVJ?
KARPAS-299 NE\UW5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwMUmyOFEh|ryP NWf3NZh5W0GQR1XS
LC4-1 MkDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwMUm1NFIh|ryP MnrCV2FPT0WU
UACC-257 MmDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjqTWM2OD1yLkG5PVQ4KM7:TR?= M4TkWXNCVkeHUh?=
EVSA-T MlzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrzTWM2OD1yLkKwN|EzKM7:TR?= M3iz[XNCVkeHUh?=
JiyoyeP-2003 NUHMSlR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjDUXh{UUN3ME2wMlIxPDd5IN88US=> MkDYV2FPT0WU
NCI-H720 NX3zPZB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLGZ3dKSzVyPUCuNlA2OjVizszN M1rOTnNCVkeHUh?=
GAK M374T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF70TYZKSzVyPUCuNlEyQDlizszN NXznUVRNW0GQR1XS
HH M3j3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWC2b45WUUN3ME2wMlIyPDB3IN88US=> NVrNRodsW0GQR1XS
NCI-H1436 M{LMcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fqWGlEPTB;MD6yNVQ3PCEQvF2= MY\TRW5ITVJ?
GR-ST NU\GNJJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTCe2dtUUN3ME2wMlIyPDh6IN88US=> M1XFdnNCVkeHUh?=
BC-1 Mn7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIP2TGRKSzVyPUCuNlI3OTZizszN Mn3BV2FPT0WU
SIG-M5 NEHyRXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPJTWM2OD1yLkKyO|I4KM7:TR?= Mne3V2FPT0WU
NCI-H345 NIfEZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrzdWVZUUN3ME2wMlI{QDB3IN88US=> MYDTRW5ITVJ?
OPM-2 NHKyb2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwMkO4PFIh|ryP MVfTRW5ITVJ?
LB1047-RCC NUfFZ49YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTBwMkS0NUDPxE1? MUfTRW5ITVJ?
CTB-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwMkS0PVMh|ryP NGnCeHVUSU6JRWK=
A3-KAW NH3TN5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwMkWzOFEh|ryP MV\TRW5ITVJ?
SF126 Mn7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2q2OmlEPTB;MD6yOVM5OyEQvF2= MY\TRW5ITVJ?
KARPAS-422 NWjXSpBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jZe2lEPTB;MD6yOVQ{PSEQvF2= NUfkcIt{W0GQR1XS
MEG-01 NYnpe|gxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwMkW2O|Mh|ryP MXzTRW5ITVJ?
NCI-H209 M4DV[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTBwMk[zO|Qh|ryP NHrBZ3pUSU6JRWK=
SBC-1 NX7y[ZhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoG3TWM2OD1yLkK2OUDPxE1? M{PxTXNCVkeHUh?=
K5 NWf1NGRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfBeG5KSzVyPUCuNlY6QDRizszN NF7xRotUSU6JRWK=
QIMR-WIL MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2WyTGlEPTB;MD6yO|E2PSEQvF2= MWjTRW5ITVJ?
NMC-G1 NHG4e2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHXeIVKSzVyPUCuNlgzOTdizszN M2Hrd3NCVkeHUh?=
IST-MES1 Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mor2TWM2OD1yLkK5NlM5KM7:TR?= MojyV2FPT0WU
SW684 M3jGeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwM{CwOFch|ryP MlzIV2FPT0WU
MV-4-11 Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHrbGNKSzVyPUCuN|A4QDhizszN MUfTRW5ITVJ?
LAN-6 NFL4SYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDqVpNKSzVyPUCuN|E2PzJizszN M3\ITnNCVkeHUh?=
RH-1 NVXGSWloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TkTWlEPTB;MD6zNVg4OSEQvF2= M33sR3NCVkeHUh?=
CP66-MEL NX61VI17T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2m4fmlEPTB;MD6zNVg4QCEQvF2= MnXvV2FPT0WU
EC-GI-10 NUW3UpF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nvOmlEPTB;MD6zNlk5PyEQvF2= MkO5V2FPT0WU
GDM-1 NF;yXFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX21NXZ3UUN3ME2wMlM{ODV7IN88US=> MYDTRW5ITVJ?
IST-SL1 NGfhbVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWT0R3hpUUN3ME2wMlM1QTF2IN88US=> NGfC[3FUSU6JRWK=
KMOE-2 MmHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1KzfWlEPTB;MD6zOVE4PSEQvF2= MV;TRW5ITVJ?
OS-RC-2 M2\KZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfhc3ZKSzVyPUCuN|U2PDRizszN MnL3V2FPT0WU
HDLM-2 MlK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLXTWM2OD1yLkO3PFE1KM7:TR?= NFznc3NUSU6JRWK=
DSH1 NH[3emZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIexRo5KSzVyPUCuN|g3OzFizszN NH7keXNUSU6JRWK=
LS-1034 M4DtSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rSXmlEPTB;MD6zPFk2PCEQvF2= MVPTRW5ITVJ?
LB373-MEL-D MorqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PGVGlEPTB;MD6zPVE6PyEQvF2= NVvSeYczW0GQR1XS
GOTO MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3r4[mlEPTB;MD60NlEyQCEQvF2= MlfVV2FPT0WU
MRK-nu-1 NIfmXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwNEKyNFUh|ryP NF;Qd5dUSU6JRWK=
SK-MM-2 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfEcWtEUUN3ME2wMlQ{PDR{IN88US=> MmDKV2FPT0WU
BOKU NX[xSXpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfDXXpKSzVyPUCuOFM4QTJizszN M3HaUXNCVkeHUh?=
NOMO-1 NFTqUmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXHTWM2OD1yLkSzPFYh|ryP MmLmV2FPT0WU
J-RT3-T3-5 NX;ib2llT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwNES4O|gh|ryP NFLmRYtUSU6JRWK=
COLO-668 NUPubZpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3f5dGlEPTB;MD60OVY3QCEQvF2= NX[wdVVPW0GQR1XS
SF539 MlfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjyXXFKSzVyPUCuOFg3QDRizszN NEnqbolUSU6JRWK=
LB2518-MEL NUDT[|U2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHoOnNWUUN3ME2wMlQ6PzB|IN88US=> MoDlV2FPT0WU
TE-441-T Ml31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwNUCxNkDPxE1? Mne0V2FPT0WU
MDA-MB-134-VI MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofGTWM2OD1yLkWwPVIyKM7:TR?= MXLTRW5ITVJ?
SCC-3 Mn[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLab|lKSzVyPUCuOVE5PzNizszN NIrxO2FUSU6JRWK=
KLE M120[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XoN2lEPTB;MD61NlE4OSEQvF2= NXX2NpU5W0GQR1XS
LB2241-RCC MmHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTBwNUK1NlUh|ryP NUXicphmW0GQR1XS
NCI-H1417 MlvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4e3XWlEPTB;MD61N|Q{PSEQvF2= MlPDV2FPT0WU
NCI-H2081 NIPlToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HzeGlEPTB;MD61PFYyOSEQvF2= NHHI[Y9USU6JRWK=
NCI-H1522 MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwNUmzPFMh|ryP NEjjb5lUSU6JRWK=
NCI-H889 MmnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XTNmlEPTB;MD61PVg1PCEQvF2= MXjTRW5ITVJ?
CGTH-W-1 NHW5XodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVv6WmF5UUN3ME2wMlYxPzV3IN88US=> MWLTRW5ITVJ?
EB-3 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Hx[GlEPTB;MD62NVE2OyEQvF2= M33IVXNCVkeHUh?=
D-336MG MmfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTtT2xOUUN3ME2wMlYyPzlzIN88US=> MmjaV2FPT0WU
LC-1F NFTWfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrjTWM2OD1yLk[yOVkzKM7:TR?= MoXtV2FPT0WU
MHH-NB-11 M2C0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnCS4tKSzVyPUCuOlM5ODFizszN MnH5V2FPT0WU
SK-N-FI NXzF[HBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnW3TWM2OD1yLk[zPVEh|ryP NEXONJpUSU6JRWK=
NCI-H69 MmryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nPSGlEPTB;MD62OFg4QSEQvF2= MnzrV2FPT0WU
SCH NV7IPVVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTnTWM2OD1yLk[2NFI{KM7:TR?= MW\TRW5ITVJ?
LS-513 MmP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwNkeyOVkh|ryP M4jHTnNCVkeHUh?=
CP67-MEL MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPUU4tZUUN3ME2wMlY4PTl4IN88US=> M{fKTnNCVkeHUh?=
GCIY NGn4OlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTBwN{CzOlMh|ryP NYDmWW14W0GQR1XS
SHP-77 NFLafFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3W2eGlEPTB;MD63NFc{PCEQvF2= NUnObFV4W0GQR1XS
EHEB NH\6NGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1O0bWlEPTB;MD63NVg2PCEQvF2= MWXTRW5ITVJ?
D-247MG NE\MVo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwN{OyN|Ih|ryP NFnWZ5dUSU6JRWK=
Raji NV7FVI1JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17reGlEPTB;MD63OFk5QSEQvF2= NUfzfVJPW0GQR1XS
MPP-89 MkO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwN{W5O|gh|ryP Mlz4V2FPT0WU
EKVX MlG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fvb2lEPTB;MD63PVA4OyEQvF2= NI[4dHBUSU6JRWK=
HCC2218 NGLnbnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XmS2lEPTB;MD63PVE{OSEQvF2= M1S4UXNCVkeHUh?=
KNS-81-FD NYrwcHp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwOEGwNVEh|ryP MVLTRW5ITVJ?
HCC2157 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TSUGlEPTB;MD64OFk2OSEQvF2= M1zhb3NCVkeHUh?=
BT-474 NV3rWYY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nwN2lEPTB;MD64PFg2PCEQvF2= NYHqeVdpW0GQR1XS
NCI-H748 M2j0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwOUGyJO69VQ>? NX\PeXl{W0GQR1XS
EW-24 M4fTZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXFRmpCUUN3ME2wMlkzODB{IN88US=> MnnVV2FPT0WU
D-263MG NHTONYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrqephKSzVyPUCuPVQ2OTJizszN Mn7LV2FPT0WU
OMC-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnVRVBKUUN3ME2wMlk3Ozd|IN88US=> Mn;XV2FPT0WU
NCI-H2196 NYfBZ41YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\oTWM2OD1yLkm3O|c4KM7:TR?= NFvQR5FUSU6JRWK=
HAL-01 M2fncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPmbolKSzVyPUCuPVk5PzJizszN MoX5V2FPT0WU
NCI-H2107 NYTVW45WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rMZWlEPTB;MT6wNVg2PCEQvF2= NHzPe2pUSU6JRWK=
LB996-RCC Mon6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XO[GlEPTB;MT6wPFA2OSEQvF2= MYfTRW5ITVJ?
NCI-H1395 MlrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3WyVWlEPTB;MT6xNFY4KM7:TR?= NVnj[WxqW0GQR1XS
CHP-126 NUmwSmNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDNTndEUUN3ME2xMlE3OTl7IN88US=> MUDTRW5ITVJ?
NB69 Mnv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13zR2lEPTB;MT6yOlE1QCEQvF2= NE\6SnJUSU6JRWK=
CAS-1 MnWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLpTWM2OD1zLkO0NlMyKM7:TR?= NFSyd|RUSU6JRWK=
JVM-3 Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{npb2lEPTB;MT60O|g2PSEQvF2= NXrtN3BPW0GQR1XS
DMS-153 M1vjZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\l[GlEPTB;MT61O|Y4PCEQvF2= NVTMdIR7W0GQR1XS
SK-MEL-2 NHfNVnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTFwN{G3PFkh|ryP MlXCV2FPT0WU
NCI-H1155 NXy3e45ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTFwN{O2O|Yh|ryP MlfSV2FPT0WU
NCI-H1092 NXWyN5FXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTFwN{[xPFIh|ryP MYTTRW5ITVJ?
LU-165 NI\id2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljUTWM2OD1zLki2OFc3KM7:TR?= NIfYPG9USU6JRWK=
HL-60 NX;HNolVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmO2TWM2OD1zLkm5PVA5KM7:TR?= Mmm3V2FPT0WU
REH NEDn[VhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPOTWM2OD1{LkCwOVgzKM7:TR?= NGWxU2dUSU6JRWK=
JVM-2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrqOGNTUUN3ME2yMlA3OTN3IN88US=> NYDwb|RVW0GQR1XS
MN-60 M2OxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1mz[WlEPTB;Mj6xO|MxQCEQvF2= M3rXRXNCVkeHUh?=
SCC-15 NV[wTVd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HHT2lEPTB;Mj6yNFI4KM7:TR?= M3m3R3NCVkeHUh?=
SNU-C1 NILhZnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37NfmlEPTB;Mj6yNVM1OyEQvF2= M4jDcnNCVkeHUh?=
SK-MEL-1 NUnXNm46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnUNG1NUUN3ME2yMlMzODR5IN88US=> NVX0b4lpW0GQR1XS
TGW MkHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnsOI1KSzVyPUKuN|UxOjdizszN MnvVV2FPT0WU
CA46 M3S4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInFW2ZKSzVyPUKuO|U6PjdizszN NGfxdo5USU6JRWK=
NCI-H23 M2DtVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PHPWlEPTB;Mj64NFc6OSEQvF2= MoOzV2FPT0WU
MMAC-SF MnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4n0SWlEPTB;Mj64OlYzQCEQvF2= MmHNV2FPT0WU
NCI-H2171 Mm\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TTXGlEPTB;Mz6wN|Q1QCEQvF2= NX7mVHFPW0GQR1XS
A704 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\IOHRKSzVyPUOuNVQyQTRizszN M4riTXNCVkeHUh?=
DB NVrqXFBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2eyXWlEPTB;Mz6yOVU4PiEQvF2= MXHTRW5ITVJ?
NCI-H719 Mkn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HMS2lEPTB;Mz6zNFM5PCEQvF2= MUDTRW5ITVJ?
MC-CAR MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPITWM2OD1|LkW0PFE4KM7:TR?= NGDtZppUSU6JRWK=
SIMA NWXD[Ys6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3OZ|FwUUN3ME2zMlU5PDF4IN88US=> MlHqV2FPT0WU
SW872 NW\Q[nBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;XcGlEPTB;Mz63PFExOSEQvF2= NVLLVnRjW0GQR1XS
HCC1187 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvYTWM2OD1|Lke4N|E2KM7:TR?= MWfTRW5ITVJ?
EW-13 M4TuW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjJTWM2OD1|LkizOFE4KM7:TR?= NX74TYxjW0GQR1XS
NCI-SNU-1 NWLxeoNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljGTWM2OD12LkKxPVk6KM7:TR?= M3rsfXNCVkeHUh?=
NCI-H226 MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXDTWM2OD12LkOzOlA3KM7:TR?= NEP0OJZUSU6JRWK=
RPMI-8866 MkLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTRwM{[wNlkh|ryP MnLtV2FPT0WU
OCI-AML2 MoK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXidJNKSzVyPUSuOVUzOyEQvF2= NY\DToVJW0GQR1XS
LU-65 NEP3fHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTRwOUOwN|Mh|ryP M4DyTXNCVkeHUh?=
SK-N-DZ M4qxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojUTWM2OD13Lk[zOFY2KM7:TR?= MW\TRW5ITVJ?
NB14 NUPzWGw{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLrbY1HUUN3ME21Mlk4OTN3IN88US=> MnrNV2FPT0WU
COLO-829 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGq3c|lKSzVyPU[uN|M{PTlizszN NUXubYVqW0GQR1XS
MHH-CALL-2 M4nEcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fYS2lEPTB;Nj61NVUxQCEQvF2= M1L6ZXNCVkeHUh?=
NCI-H1770 NXOxZXJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vYR2lEPTB;Nj62OlkxPCEQvF2= MWLTRW5ITVJ?
ECC4 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTZwOEKxO|kh|ryP MXPTRW5ITVJ?
A498 NVzzc|I1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTZwOEexPVIh|ryP M4\wPHNCVkeHUh?=
DMS-79 M{i2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TqfGlEPTB;Nz6wOFUyOiEQvF2= M{[3W3NCVkeHUh?=
P30-OHK NXX3U21CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzHTWM2OD15LkKxPVA3KM7:TR?= NWCxR|lkW0GQR1XS
D-502MG NXXPbZpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTdwOUizOkDPxE1? NY\XN2s4W0GQR1XS
RCC10RGB NXfSZYo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVi1TYFHUUN3ME24MlA3OjhizszN NUTuS3c6W0GQR1XS
U-698-M M1nndGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLITWM2OD16LkK5NlI3KM7:TR?= NW\LSJFlW0GQR1XS
BB49-HNC NUXRd5UzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXXTWM2OD17LkSyNlY2KM7:TR?= MnzqV2FPT0WU
ES1 NWDjfFhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVn4VFF1UUN3ME25MlY5QTV4IN88US=> MUfTRW5ITVJ?
MFM-223 Ml3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrhTWM2OD1zMD65PVI4KM7:TR?= NYO2VGpjW0GQR1XS
C2BBe1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlS3TWM2OD1zMT6zOVI{KM7:TR?= MYrTRW5ITVJ?
EB2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTF{Lk[4PFEh|ryP Mn7PV2FPT0WU
C8166 NF7Td41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHzTWM2OD1zMz64N|A{KM7:TR?= MYLTRW5ITVJ?
ES3 NIDWXpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfi[lNKSzVyPUGzMlk6PzdizszN MmDvV2FPT0WU
NCI-H1650 NVrwbHBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHGTWM2OD1zNj6zO|Y2KM7:TR?= M{f6ZnNCVkeHUh?=
Mo-T M1S5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\ITWM2OD1zNz60NFI6KM7:TR?= NV3CPJBHW0GQR1XS
NB7 M17vUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTnZYI1UUN3ME2xO{44PDZ5IN88US=> M1LJR3NCVkeHUh?=
ES7 NG[4TolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTF7LkW1NFch|ryP Mn;UV2FPT0WU
ES5 MojLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;jXFVKSzVyPUKxMlc3PzFizszN MYPTRW5ITVJ?
MSTO-211H NVLpOGVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnhTWM2OD1{MT64PFU5KM7:TR?= MoX6V2FPT0WU
U-87-MG Mnq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTJ3LkG5OlYh|ryP MnuyV2FPT0WU
THP-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfGTWM2OD1{OT63NlAyKM7:TR?= MofLV2FPT0WU
NB10 MnPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzjTWM2OD1|MD6yOlk1KM7:TR?= MVnTRW5ITVJ?
NH-12 Mnn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Hr[WlEPTB;M{OuNlAyPyEQvF2= NIK0ZVlUSU6JRWK=
COLO-824 Mmf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3QTWdKSzVyPUO0MlExODZizszN MYrTRW5ITVJ?
SKM-1 MljBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXYSVNWUUN3ME2zO{45PDJ{IN88US=> NV6zcWJZW0GQR1XS
NCI-H1838 NGjUWVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLhNIlKSzVyPUO4MlM4QTdizszN NV7UbpluW0GQR1XS
RL Mnj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoD6TWM2OD1|OT6yOFc4KM7:TR?= M2fkO3NCVkeHUh?=
COLO-800 MnPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\aUIRHUUN3ME20NE4xPzd|IN88US=> NFftT5lUSU6JRWK=
KG-1 NIL4[4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVH3cFhWUUN3ME20NE45QTV3IN88US=> MoewV2FPT0WU
TUR NWXHVJRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnlNZdKSzVyPUSxMlY{QTlizszN NGXFZpBUSU6JRWK=
LNCaP-Clone-FGC M3LTOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlO0TWM2OD12MT65NFE4KM7:TR?= M4HxUHNCVkeHUh?=
NCI-H322M MmDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\3UGlEPTB;NEKuOVk5PCEQvF2= MVHTRW5ITVJ?
LNCaP  NVP5ZllRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXYSVdQUUN3ME25NU4{KG6P NFfJVJkzPTVyNUG3OC=>
C4-2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Lt[WlEPTB;ODDuUS=> M{jGU|I2PTB3MUe0
JURKAT NH;6Zm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjIWFlbOjRiaB?= M2Tqe2lEPTB;NEG2MlY3KG6P M1nQeFI1PTF7OUm1
MOLT-4 NWGxfIZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;QNlQhcA>? MXjJR|UxRTJ6NUOuOUBvVQ>? MmjkNlQ2OTl7OUW=
REH NFXlXWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLhNlQhcA>? MmfoTWM2OD1{OEeuOlghdk1? M2r0N|I1PTF7OUm1
NALM-6 MmrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33rbVI1KGh? NWT6XmxDUUN3ME2zOFM{OCCwTR?= NUTafIdHOjR3MUm5PVU>
RS 4;11 Ml7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDMN5ozPCCq NXHzUIgxUUN3ME21NVkvODVibl2= NELqb2kzPDVzOUm5OS=>
697 MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoT1NlQhcA>? MXnJR|UxRTJzMEeuNUBvVQ>? MXeyOFUyQTl7NR?=
SIL-ALL M4XyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[x[ZI4OjRiaB?= NFnReGNKSzVyPUG5PU44PyCwTR?= MYKyOFUyQTl7NR?=
CEM NF7DXGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrs[IZyOjRiaB?= NXjTTGtiUUN3ME21Nk4yQCCwTR?= NWG1bYR5OjR3MUm5PVU>
P12 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHiNlQhcA>? NEDZe2FKSzVyPUO5MlI4KG6P NEPBZYgzPDVzOUm5OS=>
NALM-16 NUHnRlVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHLNlQhcA>? NVzFcYtnUUN3ME25Ok4zQCCwTR?= NWLGcItDOjR3MUm5PVU>
JURKAT NU\MRYNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWK0PEBp MUjJR|UxRTF2Lki0JI5O NFS0d4szPDVzOUm5OS=>
MOLT-4 NVnyVodTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrSOFghcA>? NGG4N4dKSzVyPUK2MlYhdk1? MYeyOFUyQTl7NR?=
REH Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rCT|Q5KGh? MULJR|UxRTR2LkexJI5O M{TtcFI1PTF7OUm1
NALM-6 NHvoeGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUC0PEBp MW\JR|UxRTJ|LkK2JI5O MVyyOFUyQTl7NR?=
RS 4;11 MnjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnOUYI1QCCq NWDUTYhNUUN3ME2xOlQvOjhibl2= M{\UV|I1PTF7OUm1
697 NF[xcFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVq0PEBp NUjKZllZUUN3ME2zNFUvOyCwTR?= Ml3VNlQ2OTl7OUW=
SIL-ALL NYDHV|lCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUm0PEBp M1HjemlEPTB;N{SuOlIhdk1? M1XqSVI1PTF7OUm1
CEM M1jTRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXW0PEBp NWLQdpJ6UUN3ME2yOE42PSCwTR?= MXmyOFUyQTl7NR?=
P12 M2LKOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLhOFghcA>? NX6xcZRqUUN3ME2xPE41PiCwTR?= M1O4[|I1PTF7OUm1
NALM-16 NV3PS4FST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPo[lJQPDhiaB?= MWDJR|UxRTZ|LkK0JI5O NF3WRXMzPDVzOUm5OS=>
JURKAT MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWP5W486PzJiaB?= NGLtR3pKSzVyPUOuOlUhdk1? Mn:3NlQ2OTl7OUW=
MOLT-4 Mn\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELwfZE4OiCq M3fzWmlEPTB;Nz6zPUBvVQ>? MYGyOFUyQTl7NR?=
REH NI\KUm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvVO|IhcA>? MUTJR|UxRTF4LkCxJI5O M{fqSlI1PTF7OUm1
NALM-6 NYPqbIpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlL5O|IhcA>? M2PvWGlEPTB;MT63PEBvVQ>? M1zzd|I1PTF7OUm1
RS 4;11 NYTVVm1[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfyN5E4OiCq MlPOTWM2OD12LkO4JI5O NUnBTVhqOjR3MUm5PVU>
697 MnLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXyO|IhcA>? NWjhcoxoUUN3ME23OE4zQCCwTR?= NH7hSJUzPDVzOUm5OS=>
SIL-ALL MofRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zoflczKGh? NEf2NnBKSzVyPUeuNkBvVQ>? NX;rcHpQOjR3MUm5PVU>
CEM NWq0elA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWK3NkBp NUPTbY95UUN3ME21MlQzKG6P NFnI[IQzPDVzOUm5OS=>
P12 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXy3NkBp M3\o[2lEPTB;Nj6zO{BvVQ>? MVKyOFUyQTl7NR?=
NALM-16 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nPWlczKGh? MXLJR|UxRTd5LkezJI5O Mn7ZNlQ2OTl7OUW=
Y79 NXzkZWZRSXCxcITvd4l{KEG|c3H5 NHrmWWkyNTVyIH7N M3XOTlEzNzJ2IHi= MkTISG1UVw>? NUL1d4tkcW6mdXPl[EBieG:ydH;zbZMhf2irY3igZ4FvKGKnIHXubIFv[2WmIHL5JGhV NHHJToQzPDN4Nk[2OS=>
WER-Rb-1 M3K0bGFxd3C2b4Ppd{BCe3OjeR?= NUfzdZlTOS13MDDuUS=> NVnB[4hkOTJxMkSgbC=> NIDuWGRFVVOR NHnBfItqdmS3Y3XkJIFxd3C2b4Ppd{B4cGmlaDDjZY4h[mViZX7oZY5k\WRiYomgTHQ> NHjUZ4wzPDN4Nk[2OS=>
G7 NHe1dWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEO1fFZKSzVyPUOuN{BvVQ>? NIPOUFEzPDJyNEezNy=>
G166 MmPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTdwMDDuUS=> NV\SNZhCOjR{MES3N|M>
CB660 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vpNWlEPTB;Nj60JI5O NVnRO3FyOjR{MES3N|M>
CB1117 M1fpbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTF3Lk[gcm0> NVKyUpFFOjR{MES3N|M>
KB-3-1 NVz0W3JST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLITWM2OD1zLkS4JOKyKDBwNUOgcm0> M3LSWFI{QTZ{NES1
KB-8-5-11 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFv2dHVKSzVyPUWuNFEhyrFiMj6wNUBvVQ>? Mn[3NlM6PjJ2NEW=
KB-C-1 Ml;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\WWGlEPTB;MU[uO|YhyrFiND61NUBvVQ>? M3LZVFI{QTZ{NES1
KB-V-1 MlPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\ybnhKSzVyPUK4NU4zPCEEsTCzNU42PyCwTR?= NXrXdm97OjN7NkK0OFU>
OVCAR-8 M2LyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moi1TWM2OD15LkG5JOKyKDNwNkCgcm0> MlzrNlM6PjJ2NEW=
NCI-ADR-RES Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XOb2lEPTB;MUK3N{4{OCEEsTCxPVEvOjBibl2= MoGzNlM6PjJ2NEW=
MCF7 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTVwMUGgxtEhOS52NzDuUS=> M373fVI{QTZ{NES1
MCF7-FLV1000 Ml3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTN7Mz6xPEDDuSB5ND64N{BvVQ>? MXqyN|k3OjR2NR?=
S1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLBdGlKSzVyPUK0MlMxKMLzIESuO|Uhdk1? MVqyN|k3OjR2NR?=
S1-M1-80 NX;KdZpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTJ4MT6wOkDDuSB2OD6yOUBvVQ>? MVuyN|k3OjR2NR?=
CORL-23/P NX3kZW53T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnBTWM2OD12LkO4JOKyKDFwMkWgcm0> NXLCWGc{OjN7NkK0OFU>
CORL-23/R M{LQSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTVwMU[gxtEhOS56MzDuUS=> NGHCS5YzOzl4MkS0OS=>
NIH3T3 M{TWbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LUWWlEPTB;NECuOlAhyrFiND65O{BvVQ>? M2DtOlI{QTZ{NES1
NIH3T3-G185 NEHXOZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvKfIZKSzVyPUK0NVMvPDBiwsGgOFI{NjZ4IH7N MnHSNlM6PjJ2NEW=
pcDNA-HEK293 NFrvcXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnyZ3VXUUN3ME2yMlc2KMLzIECuOlchdk1? NFqzcmYzOzl4MkS0OS=>
MDR19-HEK293 MlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjqTWM2OD16NT61NEDDuSBzMz62O{BvVQ>? MonnNlM6PjJ2NEW=
R482-HEK293 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTJ3Lkm3JOKyKDRwOUWgcm0> MnP0NlM6PjJ2NEW=
MRP1-HEK293 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLke4R7UUN3ME2yMlk6KMLzIEGuOFkhdk1? NHLHUWEzOzl4MkS0OS=>
SF188 M1nLXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3qUW8yOC1zMECgcm0> Mn3JNlQuQTZiaB?= NWXpVGNQTE2VTx?= NFLtPFlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CClb37j[Y51emG2aX;uMUBl\XCnZHXueEBu[W6wZYK= NGfh[ZozOzh6N{[0OS=>
T98G NETvOFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLkfZgyOC1zMECgcm0> M1z0PVI1NTl4IHi= M{PUOGROW09? M2HMVIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHPvcoNmdnS{YYTpc44uKGSncHXk[Y51KG2jbn7ldi=> MVWyN|g5PzZ2NR?=
DU145 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDEUXNQ M3faZmlEPTEkiMy2NEBvVQ>? NWL6e4dqOjN6OES0Nlg>
LNCaP  Mmr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfUSG1UVw>? MX\JR|Ux6oj:N{Wgcm0> MnLsNlM5QDR2Mki=
PC3 NHnYb5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrQSG1UVw>? M3Sxb2lEPTEkiMyxO|Uhdk1? NWTXeFM1OjN6OES0Nlg>
RT4 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\ibGlEPTB;MkeuNlEhdk1? NUfEZ4xQOjN5OUK2N|k>
5637 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkD0TWM2OD12NT60O{BvVQ>? NGfkPYIzOzd7Mk[zPS=>
T24 M3K5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnmZXY3UUN3ME23PU4yOiCwTR?= MmntNlM4QTJ4M{m=
MCF7  MnniSpVv[3Srb36gRZN{[Xl? NUjOeW9zOTByIH7N Mn3sNUBp MXXEUXNQ M2DHTpJm\HWlZYOgeIhmKGmwZIXjeIlwdiCxZtMgS5Jm[jFuwrDT[4syNMLiUIOyMOKhW2W{cHnuZVMtKGGwZNMgW4l{eDJ? NET1PIwzOzd5MEK0OC=>
KB-V1  NHLre2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIOydpRKSzVyPUOuPVIh|ryP NGL6ZnczOzV7M{G5Oi=>
Hec50co M3PWdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWqxc2RHUUN3ME21JI5O M{XNZ|I{OTR4Nki3
MDA-MB-468 MlXaRZBweHSxc3nzJGF{e2G7 M1HJVVEwPS9zMDDuUS=> NFHrSYEzPC92OD:3NkBp MoTBSG1UVw>? NIHNeplqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MXGyN|E1PDJ7NB?=
MCF10A NWThUWt6SXCxcITvd4l{KEG|c3H5 NFywRpAyNzVxMUCgcm0> MXeyOE81QC95MjDo MmrNSG1UVw>? NWGyZllwcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NWGxS4dWOjNzNESyPVQ>
Huh-7 NF\VVHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUOxM|ExNzFyMD:xNFAxKG6P MmLSOFghcA>? MUnk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JIRwe2VvZHXw[Y5l\W62bIm= MUOyNlc1PTV6Nx?=
Daoy  M3XiUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\JOlEvQDd3LUK0NEBvVQ>? MWK3NkBp NVjRTIZoTE2VTx?= NUO4bVNvUUN3ME21JI5O MVOyNlM6ODJ5OR?=
ONS-76 M1\DZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{ewSFEvQDd3LUK0NEBvVQ>? MXS3NkBp MVHEUXNQ NHntS5RKSzVyPUeuOUBvVQ>? NH3V[4EzOjN7MEK3PS=>
SUM 149 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3i1UFAuOTByIH7N NH;Gd2g4OiCq MlrpbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnHy NEDOeYozOjNyOUmzPS=>
MDA-MB-231 MnfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEH5R2wxNTFyMDDuUS=> M13JUlczKGh? NID1[5JqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7uZZI> M1jZd|IzOzB7OUO5
HR5 NIr3eYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnmWJExNTFyMDDuUS=> NXvxUG1TPzJiaB?= M4SwOolvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7hdi=> MUSyNlMxQTl|OR?=
BT-474-M1 NH:0c5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jB[VAuOTByIH7N NIrZTmM4OiCq M2DmbolvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7hdi=> MX2yNlMxQTl|OR?=
AU565 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfQ[oJ4OC1zMECgcm0> NX;mZ3hXPzJiaB?= MUTpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wYYK= MWCyNlMxQTl|OR?=
T47D MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPsPHpWOC1zMECgcm0> NV:yfItVPzJiaB?= MV3pcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wYYK= NH6wdZIzOjNyOUmzPS=>
MCF7 NHnYe3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYeyd2ZIOC1zMECgcm0> NXnidYxqPzJiaB?= M3\3TolvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7hdi=> M{fUU|IzOzB7OUO5
HCT116p53(+/+) NGTaUJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXOySHRIOTBvMUCwNEBvVQ>? NGSwWIgzPC92ODDo MYfpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gZ49ueGyndHXsfUBifCB{NTDuUS=> M{LZbFIzOjZ{MUex
HCT116p53(-/-) M{K2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1:xV|ExNTFyMECgcm0> NFvlVJEzPC92ODDo NVX1fI5IcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGOxbYDs[ZRmdHliYYSgNlUhdk1? NIHMcVczOjJ4MkG3NS=>
HeLa  NYX2NopTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUexNE0yODBibl2= MV60PEBp M3PoRmROW09? NHSwc5FKSzVyPUWyMlkhdk1? MV:yNlA5ODJ|NR?=
HeLa  NULXRWJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DHVFExNTFyMDDuUS=> MXy3NkBp Mo\xSG1UVw>? Mn;MTWM2OD13MD61JI5O Mnf3NlIxQDB{M{W=
GBC Mnj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPIO|IhcA>? MlXRTWM2OD1zND63PEBvVQ>? NYDybopuOjF7NkW3N|k>
GB-CL-1 NVmzXmFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkX0O|IhcA>? NY\JeHB2UUN3ME21MlIzKG6P MmfqNlE6PjV5M{m=
Mz-ChA-2 NVP2U3NRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvW[IxzPzJiaB?= MonSTWM2OD1|LkOxJI5O M1eyd|IyQTZ3N{O5
TGBC1-TKB MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFGzSWQyPDRiaB?= MXzJR|UxRTZwN{Kgcm0> M2fUSVIyQTZ3N{O5
Wittier MmK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDoVIg4OiCq NXrlSpFiUUN3ME2zMlI3KG6P MWOyNVk3PTd|OR?=
H-1 NHTxbpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFf2UpA4OiCq MWTJR|UxRTlwNUSgcm0> NHrmS|IzOTl4NUezPS=>
HuH-28 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFr1[Gs4OiCq Mn\6TWM2OD1zMT6xPUBvVQ>? NV\Zc3VXOjF7NkW3N|k>
NEC NGD2fmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjNenJSPzJiaB?= MmnFTWM2OD17Lkm4JI5O MUWyNVk3PTd|OR?=
REB MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjxSnJ[PzJiaB?= MX;JR|UxRTF|LkWxJI5O MnPlNlE6PjV5M{m=
CC-LP-1 MoiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWOzOG9lPzJiaB?= MWjJR|UxRTVwOESgcm0> MYeyNVk3PTd|OR?=
CC-SW-1 NWT6SItMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWC3NkBp MoO3TWM2OD17LkW1JI5O NHj0cVYzOTl4NUezPS=>
EGI-1 M1jze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{G5dVczKGh? M33ufWlEPTB;MUCuO|Ihdk1? MoTvNlE6PjV5M{m=
Sk-ChA-1 M3jqeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWi3NkBp Mn7GTWM2OD1zNz6yJI5O NWrqPW1uOjF7NkW3N|k>
TFK-1 NYPkXlJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXXd2JJPzJiaB?= MVLJR|UxRTF|LkS1JI5O NFuxRWEzOTl4NUezPS=>
786-O NGXpVFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlS2OU05OCCwTR?= M3PERVk3KGh? NEjjb5ZJS2x? M1X4cJN2eHC{ZYPz[ZMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIhf2m2aDDJR|UxyqC4YXz1[ZMhd2ZiMjD0c{AzOCCwTR?= MojGNlE3PDJ|N{S=
A498 NEHlWpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIX4NnE2NThyIH7N NXfve|U2QTZiaB?= NUH1d5c3UEOu MWfzeZBxemW|c3XzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJJdqfGhiSVO1NOKhfmGudXXzJI9nKDJidH:gNlAhdk1? NGH5WIYzOTZ2MkO3OC=>
ACHN NGXr[WdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TDcVUuQDBibl2= M2OzcVk3KGh? MWnIR4w> MVPzeZBxemW|c3XzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJJdqfGhiSVO1NOKhfmGudXXzJI9nKDJidH:gNlAhdk1? NGHCc|YzOTZ2MkO3OC=>
Caki-1 NWfUfnVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYW1MVgxKG6P NGT3Xo86PiCq NET3cVRJS2x? NE\2ZWd{fXCycnXzd4V{KHSqZTDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKHerdHigTWM2OMLidnHseYV{KG:oIEKgeI8hOjBibl2= NH3XdWgzOTZ2MkO3OC=>
SN12C NHXCOG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV21MVgxKG6P NG\5SYU6PiCq M{LPTWhEdA>? MVzzeZBxemW|c3XzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJJdqfGhiSVO1NOKhfmGudXXzJI9nKDJidH:gNlAhdk1? NEjXTHgzOTZ2MkO3OC=>
HMC-1.1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXQOFN1OS1zMECwJI5O NWLZOGZ7PzJiaB?= MnLJbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5m M{TxclIyOjR{MUi5
HMC-1.2 NW\0PZk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUOxMVExODBibl2= MU[3NkBp MXPpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoU> M{\ad|IyOjR{MUi5
C2 NV;IeXd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX2xMVExODBibl2= MlXpO|IhcA>? MmmxbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5m Mn;SNlEzPDJzOEm=
CHP-212 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILzUIgyNTF{NTDuUS=> MUWyOE0yOjBiaB?= NHHURopqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l NVXZTYgxOjFzNkmyOFI>
IMR-32 NWDSTnU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXxUWJVOS1zMkWgcm0> NF3mTJAzPC1zMkCgbC=> MortbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?= MluzNlEyPjl{NEK=
Kelly Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\VdlEuOTJ3IH7N NH21XXozPC1zMkCgbC=> MlnVbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?= M3rROFIyOTZ7MkSy
SH-EP MoHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nzbFEuOTJ3IH7N MorFNlQuOTJyIHi= NEm0WI9qdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l MoWzNlEyPjl{NEK=
SH-SY5Y MnHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVSxMVEzPSCwTR?= NHrp[IkzPC1zMkCgbC=> NELMOZBqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l Moj6NlEyPjl{NEK=
SK-N-AS NELNSYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfyV5pOOS1zMkWgcm0> MVSyOE0yOjBiaB?= M2\yW4lvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW= NGrDeXozOTF4OUK0Ni=>
SK-N-BE MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFX4[noyNTF{NTDuUS=> NEHjcFgzPC1zMkCgbC=> Mn\SbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?= MmnWNlEyPjl{NEK=
KG1 MnrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXwUm4yNzFyL{GwNEBvVQ>? M37nSFczKGh? M1q2[GROW09? NIDyNopqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l Ml:yNVk1PTh|NUi=
U937 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHP4eJkyNzFyL{GwNEBvVQ>? NF;j[Y04OiCq NXzV[XhXTE2VTx?= MU\pcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n MWexPVQ2QDN3OB?=
CAL62 NHHY[IxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnsVFYxOC5zLUGwNEBvVQ>? MWG3NkBp MoToSG1UVw>? MUnFR|UxRTFwNDDuUS=> NUjWU3R[OTl{MkO1OVM>
OCUT-1 NEn0[oJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4L3OFAvOS1zMECgcm0> M{SwRlczKGh? M2r5ZWROW09? MWfFR|UxRTJwMzDuUS=> NWjPO402OTl{MkO1OVM>
8505C M2jKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvldFFiOC5zLUGwNEBvVQ>? M{DuO|czKGh? M3Lhb2ROW09? NUi3XJU5TUN3ME2zMlIhdk1? MWKxPVIzOzV3Mx?=
ACT-1 NXjUPVVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWm3OlIzOC5zLUGwNEBvVQ>? NFza[IE4OiCq NUj0NFdLTE2VTx?= M3rpVmVEPTB;NT60JI5O M1rwNVE6OjJ|NUWz
SW1736 M4jsT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXqwMlEuOTByIH7N Ml7uO|IhcA>? NUDpXWxqTE2VTx?= M{KzUmVEPTB;NT62JI5O Mm\tNVkzOjN3NUO=

... Click to View More Cell Line Experimental Data
In vivo BI 2536 given i.v. once or twice per week is highly efficacious in diverse xenograft models with acceptable tolerability by inhibiting cell proliferation through a mitotic arrest, and subsequently induction of tumor-cell death. Administration of BI 2536 at 50 mg/kg once or twice per week significantly inhibits growth of HCT 116 xenografts with T/C of 15% and 0.3%, respectively. BI 2536 treatment twice-weekly also leads to excellent tumor-growth in BxPC-3 and A549 models with T/C of 5% and 14%, respectively. [1]

Protocol

Kinase Assay:[1]
+ Expand

Plk1 in vitro kinase assay:

Recombinant human Plk1 (residues 1-603) is expressed as N-terminal, GST-tagged fusion protein with a baculoviral expression system and purified by affinity chromatography with Glutathione-agarose. Enzyme activity assays for Plk1 are performed in the presence of serially diluted BI 2536 with 20 ng of recombinant kinase and 10 μg casein from bovine milk as the substrate. Kinase reactions are performed in a final volume of 60 μL for 45 minutes at 30 °C (15 mM MgCl2, 25 mM MOPS [pH 7.0], 1 mM DTT, 1% DMSO, 7.5 mM ATP, 0.3 μCi γ-33P-ATP). Reactions are terminated by the addition of 125 μL of ice-cold 5% TCA. After transfer of the precipitates to Multi-Screen mixed ester cellulose filter plates, plates are washed with 1% TCA and quantified radiometrically. Dose-response curve is used for calculating IC50 value.
Cell Research:[1]
+ Expand
  • Cell lines: HeLa, A43, SKOV-3, HT-29, K562, A549, Saos-2, MCF7, HCT116, COLO 205, Hep G2, Raji and PC-3 cells, etc.
  • Concentrations: Dissolved in DMSO, final concentrations ~1 μM
  • Incubation Time: 24 and 72 hours
  • Method: Cells are exposed to various concentrations of BI 2536 for 24, and 72 hours. Cell growth is assessed by the measurement of Alamar Blue dye conversion in a fluorescence spectrophotometer. For determining the DNA content of the cultures, cell suspensions are fixed in 80% ethanol, treated for 5 minutes with 0.25% Triton X-100 in PBS, and incubated with 0.1% RNase and 10 μg/mL propidium iodide (PI) in PBS for 20 minutes at RT. Cell-cycle profiles are determined by flow cytometric analysis.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female BomTac:NMRI-Foxn1nu mice injected subcutaneously with HCT 116, NCI-H460, or A549 cells
  • Formulation: Formulated in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl
  • Dosages: ~50 mg/kg
  • Administration: Injection i.v. once or twice per week
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 100 mg/mL (191.69 mM)
DMSO 21 mg/mL (40.25 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG 400+0.5% Tween 80+5% Propylene glycol
For best results, use promptly after mixing. 		15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 521.66
Formula

C28H39N7O3
CAS No. 755038-02-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00526149 Completed Breast Cancer|Endometrial Cancer|Head and Neck Cancer|Melanoma (Skin)|Ovarian Cancer|Sarcoma European Organisation for Research and Treatment of Cancer - EORTC July 2007 Phase 2
NCT02215044 Terminated Pancreatic Neoplasms Boehringer Ingelheim June 2007 Phase 1
NCT00412880 Completed Carcinoma Small Cell Boehringer Ingelheim January 2007 Phase 2
NCT02211833 Completed Carcinoma Non-Small-Cell Lung Boehringer Ingelheim October 2006 Phase 1
NCT00701766 Completed Leukemia Myeloid Acute Boehringer Ingelheim October 2006 Phase 2
NCT00706498 Completed Prostatic Neoplasms Boehringer Ingelheim September 2006 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    We need to use BI 2536 in preclinical studies using mice, how to formulate the inhibitor for this in vivo study?

  • Answer:

    For in vivo study, DMSO should not be more than 5% because the toxicity. You can formulated BI2536 in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl for animal study according to the reference :( Supplemental Data) http://linkinghub.elsevier.com/retrieve/pii/S0960-9822(06)02671-6

selleck catalog

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

  • Selective Plk Inhibitors

    GSK461364 : Plk1-selective, Ki=2.2 nM.

  • Plk Inhibitor in Clinical Trial

    Rigosertib (ON-01910) : Phase III for Myelo Dysplastic Syndrome (MDS).

  • Newest Plk Inhibitor

    Ro3280 New : Potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.

  • Calssic Plk Inhibitor

    Volasertib (BI 6727) : Highly potent Plk1 inhibitor with IC50 of 0.87 nM and in phase II trials.

Related PLK Products

  • SBE 13 HCl New

    SBE 13 HCl is a potent and selective PLK1 inhibitor with IC50 of 200 pM, >4000-fold selectivity over Aurora A kinase, Plk2 and Plk3.

  • Ro-3306 New

    RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

  • CCG-1423 New

    CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.

  • Rigosertib (ON-01910)

    Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay. It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. Phase 3.

  • HMN-214

    HMN-214 is a prodrug of HMN-176, which alters the cellular spatial orientation of Plk1.

  • GSK461364

    GSK461364 inhibits purified Plk1 with Ki of 2.2 nM in a cell-free assay. It is more than 1000-fold selective against Plk2/3. Phase 1.

    Features:Demonstrates >390-fold selectivity for Plk1 relative to Plk2 and Plk3.

  • Volasertib (BI 6727)

    Volasertib (BI 6727) is a highly potent Plk1 inhibitor with IC50 of 0.87 nM in a cell-free assay. It shows 6- and 65-fold greater selectivity against Plk2 and Plk3. Phase 3.

    Features:A high volume of distribution, indicating good tissue penetration, and a long terminal half-life.

  • MLN0905

    MLN0905 is a potent inhibitor of PLK1 with IC50 of 2 nM.

  • Ro3280

    RO3280 is a potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.

    Features:A selective PLK1 inhibitor. Demonstrates greater potency than BI2536. Potential use in nasopharyngeal carcinomas.

  • NMS-P937 (NMS1286937)

    NMS-P937 (NMS1286937) is an orally available, selective Polo-like Kinase 1 (PLK1) inhibitor with IC50 of 2 nM, 5000-fold selectivity over PLK2/PLK3. Phase 1.

Tags: buy BI 2536 | BI 2536 supplier | purchase BI 2536 | BI 2536 cost | BI 2536 manufacturer | order BI 2536 | BI 2536 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID